In This Article:
We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Ibio, Inc. (NYSEAMERICAN:IBIO) stands against other stocks that insiders are buying this year.
Even though this is just the beginning of the year, we thought it might be interesting to see what stocks have attracted the most attention from insiders. Why? Sometimes, when executives or insiders acquire shares early in the year, it could mean that they expect strong financial results or positive company developments.
On the other hand, insiders sometimes sell shares at the beginning of the year for tax reasons. For example, they can sell shares to harvest tax loss or to balance out gains/losses from the previous year.
Both insider selling and buying can be driven by various motives, however, it’s important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions. That’s why due diligence before any investment is of the utmost importance. However, insider trading activity in combination with other relevant determinants can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.
To identify the 10 stocks insiders are buying this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five insiders buying since the beginning of the year. With each stock, we note the number of insiders who recently bought shares.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A biotechnologist in a lab wearing an apron and safety glasses, working on a biopharmaceutical process.
Ibio, Inc. (NYSEAMERICAN:IBIO)
Number of Insiders Buying: 7
Ibio, Inc. (NYSEAMERICAN:IBIO) is a biotech company focused on using AI and advanced computational biology to develop and design next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of new antibody treatments to address various unmet needs.
For the second quarter ended Dec. 31, 2024, Ibio reported revenue of $200,000. Net loss amounted to $4.36 million, which compares to net loss of $4.49 million in the same period last year.